Neuropsychiatric Characteristics of GBA-associated Parkinson Disease
Overview
Authors
Affiliations
Mutations in GBA1 are a well-established risk factor for Parkinson disease (PD). GBA-associated PD (GBA-PD) may have a higher burden of nonmotor symptoms than idiopathic PD (IPD). We sought to characterize the relationship between GBA-PD and neuropsychiatric symptoms. Subjects were screened for common GBA1 mutations. GBA-PD (n=31) and non-carrier (IPD; n=55) scores were compared on the Unified Parkinson Disease Rating Scale (UPDRS), Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI), and the State-Trait Anxiety Index (STAI). In univariate comparisons, GBA-PD had a greater prevalence of depression (33.3%) versus IPD (13.2%) (p<0.05). In regression models controlling for age, sex, disease duration, motor disability, and MoCA score, GBA-PD had an increased odds of depression (OR 3.66, 95% CI 1.13-11.8) (p=0.03). Post-hoc analysis stratified by sex showed that, among men, GBA-PD had a higher burden of trait anxiety and depression than IPD; this finding was sustained in multivariate models. Among women, GBA-PD did not confer greater psychiatric morbidity than IPD. These results suggest that GBA1 mutations confer greater risk of neuropsychiatric morbidity in PD, and that sex may affect this association.
A Global Perspective of -Related Parkinson's Disease: A Narrative Review.
Koros C, Bougea A, Alefanti I, Simitsi A, Papagiannakis N, Pachi I Genes (Basel). 2025; 15(12.
PMID: 39766872 PMC: 11675599. DOI: 10.3390/genes15121605.
Avenali M, Zangaglia R, Cuconato G, Palmieri I, Albanese A, Artusi C J Neurol Neurosurg Psychiatry. 2023; 95(4):309-315.
PMID: 37879897 PMC: 10958298. DOI: 10.1136/jnnp-2023-332387.
Dysphagia in Parkinson Disease: Part I - Pathophysiology and Diagnostic Practices.
Rudisch D, Krasko M, Burdick R, Broadfoot C, Rogus-Pulia N, Ciucci M Curr Phys Med Rehabil Rep. 2023; 11(2):176-187.
PMID: 37608845 PMC: 10441627. DOI: 10.1007/s40141-023-00392-9.
GBA1 Variants and Parkinson's Disease: Paving the Way for Targeted Therapy.
Huh Y, Usnich T, Scherzer C, Klein C, Chung S J Mov Disord. 2023; 16(3):261-278.
PMID: 37302978 PMC: 10548077. DOI: 10.14802/jmd.23023.
The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease.
Debroff J, Omer N, Cohen B, Giladi N, Kestenbaum M, Shirvan J Mov Disord Clin Pract. 2023; 10(4):606-616.
PMID: 37070047 PMC: 10105114. DOI: 10.1002/mdc3.13722.